ClinicalTrials.gov 临床试验·· 2 天前AI 评分22
ROC-101 治疗肺动脉高压(PAH)及间质性肺病相关肺高压(ILD-PH)的 ROCSTAR 研究
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AI 导读
ROCSTAR 研究正在评估 ROC-101 用于成人肺动脉高压(PAH)及间质性肺病相关肺高压(ILD-PH)患者的效果。受试者在标准治疗(SOC)基础上加用 ROC-101,治疗期为 24 周,随后进入长期扩展期,持续至项目结束或产品获批上市。
来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov